This Drug Stock Has Crushed the S&P 500 Over the Last Decade
Sales of Eli Lilly’s (LLY +2.57%) Mounjaro and Zepbound have been nothing short of amazing. The two GLP-1 drugs saw sales increases of 99% and 175%, respectively, in 2025. The company is at the forefront of this still-developing drug niche. No wonder Eli Lilly’s stock is up more than 1,100% over the past decade, handily…